Skip to main content
Premium Trial:

Request an Annual Quote

Apton Biosystems Raises $24M in Series A Funding

NEW YORK – Apton Biosystems, a Pleasanton, California-based firm developing sequencing and protein detection technology, said on Wednesday that it has raised $24 million in Series A financing.

Kern Capital led the round, joined by Casdin Capital and Khosla Ventures. Jay Kern has joined Apton's board of directors.

The firm plans to use the funding to continue development of its Super-Res sequencing and single-molecule proteomics detection systems.

"Genomics and advanced proteomics are utilized in a minority of clinical applications today, but have the potential to unlock the answers to every facet of human biology," Apton CEO John Hanna said in a statement. "This funding allows us to continue building the team and technology to address the challenges in reaching the scale necessary for routine clinical use."

Founded in 2012, Apton has designed optical systems for sequencing and protein detection. It has also received funding from Samsung Catalyst Fund and Cowen Investments.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.